PDP. Murali Doraiswamy

P. Murali Doraiswamy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


P. Murali Doraiswamy has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alzheimer’s Disease and the Glutamate NMDA Receptor

    by P. Murali Doraiswamy, Md

    Current treatment of Alzheimer’s disease (AD) has focused on the use of cholinesterase inhibitors. This review emphasizes emerging therapies for the treatment and/or prevention of AD, with a focus on glutamatergic excitotoxicity in dementia and the therapeutic promise of the uncompetitive, low- to moderate-affinity N-methyl-D-aspartate (NMDA) receptor antagonist, memantine. Preclinical studies and clinical trials in AD, as well as the extensive clinical use of memantine for neurodegenerative conditions in Europe since 1982, support the safety, tolerability, and efficacy of this agent. Memantine was recently approved in Europe for the treatment of moderately severe to severe AD and is an investigational drug in the United States. Psychopharmacology Bulletin. 2003;37(2):41-49.


  • Atypical Antipsychotics and Pituitary Neoplasms in the WHO Database

    by P. Murali Doraiswamy, Md, Gisela Schott, Mph, Kristina Star, Rn, Ralph Edwards, Bruno Mueller-Oerlinghausen

    Amisulpride and risperidone had among the highest Information Component (IC) scores for benign pituitary neoplasm: amisulpride (IC = 3.31, IC025 = 1.83, 5 reports) and risperidone (IC = 4.03, IC025 = 3.33, 19 reports), and not otherwise specified (NOS) pituitary neoplasm: amisulpride (IC = 2.69, IC025 = 0.70, 3 reports) and risperidone (IC = 4.49, IC025 = 3.86, 23 reports). Psychopharmacology Bulletin. 2007;40(1):74-76.

  • Donepezil for Cognitive Decline Following Coronary Artery Bypass Surgery: A Pilot Randomized Controlled Trial

    by P. Murali Doraiswamy, Md, Michael A. Babyak, Ph D, Therese Hennig, Pa- C, Ranak Trivedi, William D. White, Mph, Joseph P. Mathew, et al.

    Objective: To study the effect of donepezil in treating patients with cognitive decline following coronary artery bypass graft (CABG) surgery. Methods: Forty-four patients, with at least a 0.5 SD decline at 1 year post-CABG on at least one cognitive domain compared to their pre-CABG baseline score, were randomized to treatment with donepezil (titrated to 10 mg daily) or placebo in a 12-week double-blind, single center, randomized study. A composite cognitive change score served as the primary outcome. Secondary outcome measures included tests of memory, attention, psychomotor speed, and executive function. Results: The composite cognitive outcome did not show significant treatment effects. Secondary measures varied in their sensitivity to donepezil effects with the largest effects seen on the Wechsler Visual Memory Scale-Delayed and Immediate recall tests. More than twice (52% vs. 22%) as many donepezil-treated patients showed a significant improvement compared with placebo patients on Delayed recall. Tests with weak effect sizes and minimal trends favoring donepezil were the Boston Naming and Digit Symbol. However, most of the other instruments (e.g., Digit Span, Trails B, and Controlled Word Association) showed no treatment benefits. More donepezil-treated than placebo-treated patients experienced diarrhea, but other adverse effects and safety measures did not differ between groups. Conclusion: In the post-CABG mild cognitive decline setting, donepezil did not improve composite cognitive performance but improved some aspects of memory. Donepezil was well tolerated and had no significant effects on EKG parameters. Because of limitations such as small sample size and multiplicity of tests, these findings are preliminary but add to our knowledge of cholinergic effects in vascular mild cognitive decline. Psychopharmacology Bulletin. 2007;40(2):54–62.


  • The ADNI Publication Policy: Commensurate recognition of critical contributors who are not authors

    by Orest Hurko, Sandra E. Black, Rachelle Doody, P. Murali Doraiswamy, Anthony Gamst, Jeffrey Kaye, Thomas O. Obisesan, Henry Rusinek, Doug Scharre, Reisa Sperling, et al.


  • Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDS‐C16 and QIDS‐SR16) in the elderly

    by P. M. Doraiswamy, I. H. Bernstein, A. J. Rush, Y. Kyutoku, T. J. Carmody, L. Macleod, S. Venkatraman, M. Burks, D. Stegman, B. Witte, et al.

    Doraiswamy PM, Bernstein IH, Rush AJ, Kyutoku Y, Carmody TJ, Macleod L, Venkatraman S, Burks M, Stegman D, Witte B, Trivedi MH. Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDS‐C16 and QIDS‐SR16) in the elderly.Objective:  To evaluate psychometric properties and comparability ability of the Montgomery‐Åsberg Depression Rating Scale (MADRS) vs. the Quick Inventory of Depressive Symptomatology–Clinician‐rated (QIDS‐C16) and Self‐report (QIDS‐SR16) scales to detect a current major depressive episode in the elderly.Method:  Community and clinic subjects (age ≥60 years) were administered the Mini‐International Neuropsychiatric Interview (MINI) for DSM‐IV and three depression scales randomly. Statistics included classical test and Samejima item response theories, factor analyzes, and receiver operating characteristic methods.Results:  In 229 elderly patients (mean age = 73 years, 39% male, 54% current depression), all three scales were unidimensional and with nearly equal Cronbach α reliability (0.85–0.89). Each scale discriminated persons with major depression from the non‐depressed, but the QIDS‐C16 was slightly more accurate.Conclusion:  All three tests are valid for detecting geriatric major depression with the QIDS‐C16 being slightly better. Self‐rated QIDS‐SR16 is recommended as a screening tool as it is least expensive and least time consuming.


  • Does Meditation Enhance Cognition and Brain Plasticity?

    by Glen L. Xiong, P. Murali Doraiswamy

    Meditation practices have various health benefits including the possibility of preserving cognition and preventing dementia. While the mechanisms remain investigational, studies show that meditation may affect multiple pathways that could play a role in brain aging and mental fitness. For example, meditation may reduce stress‐induced cortisol secretion and this could have neuroprotective effects potentially via elevating levels of brain derived neurotrophic factor (BDNF). Meditation may also potentially have beneficial effects on lipid profiles and lower oxidative stress, both of which could in turn reduce the risk for cerebrovascular disease and age‐related neurodegeneration. Further, meditation may potentially strengthen neuronal circuits and enhance cognitive reserve capacity. These are the theoretical bases for how meditation might enhance longevity and optimal health. Evidence to support a neuroprotective effect comes from cognitive, electroencephalogram (EEG), and structural neuroimaging studies. In one cross‐sectional study, meditation practitioners were found to have a lower age‐related decline in thickness of specific cortical regions. However, the enthusiasm must be balanced by the inconsistency and preliminary nature of existing studies as well as the fact that meditation comprises a heterogeneous group of practices. Key future challenges include the isolation of a potential common element in the different meditation modalities, replication of existing findings in larger randomized trials, determining the correct “dose,” studying whether findings from expert practitioners are generalizable to a wider population, and better control of the confounding genetic, dietary and lifestyle influences.


  • PET Scanning in Mild Cognitive Impairment

    by P Murali Doraiswamy

    The report by Small and colleagues (Dec. 21 issue)1 on the use of positron-emission tomography (PET) after injection of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl} ethylidene) malononitrile (FDDNP) to estimate the risk of Alzheimer's disease in persons with mild cognitive impairment raises the question of the clinical criteria for the diagnosis of this disease. The current criteria of the National Institute of Neurological Disorders and Stroke–Alzheimer's Disease and Related Disorder Association for diagnosing Alzheimer's disease clinically are 20 years old. If FDDNP-PET is validated, it will pose several questions.


  • Pharmacological strategies for the prevention of Alzheimer’s disease

    by P Murali Doraiswamy, Glen L Xiong

    This review examines key pharmacological strategies that have been clinically studied for the primary or secondary prevention of Alzheimer’s disease. Much information (neuropsychological, genetic and imaging) is already available to characterise an individual’s risk for developing Alzheimer’s disease. However, regulatory pathways for obtaining a prevention indication are less well charted, and such trials tend to involve 3- to 7-year studies of 1000 – 5000 individuals, depending on baseline status. Treatments developed for prevention will also need to have superior safety. For these reasons, > 100 proprietary pharmacological products are currently being developed for an Alzheimer’s disease treatment, but only a few are being studied for prevention. Randomised trial data are available for antihypertensive agents (calcium channel blockers, angiotensin-converting enzyme inhibitors), pravastatin, simvastatin, conjugated oestrogen, raloxifene, rofecoxib, CX516 (AMPA agonist) and cholinesterase inhibitors regar...


  • Open Access

    Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem

    by Ana Szarfman, Joseph M. Tonning, P. Murali Doraiswamy

    The large number of adverse‐event reports generated by marketed drugs and devices argues for the application of validated computerized algorithms to supplement traditional methods of detecting adverse‐event signals. Difficulties in accurately estimating patient exposure and background rates for a given event in a specific population hinder risk estimation in spontaneous adverse‐event databases. The United States Food and Drug Administration (FDA) is evaluating a Bayesian data mining system called Multi‐item Gamma Poisson Shrinker (MGPS) to enhance the FDA's ability to monitor the safety of drugs, biologics, and vaccines after they have been approved for use. The MGPS computes adjusted higher‐than‐expected reporting relationships between drugs and adverse events across 35 years of data relative to internal background rates. The MGPS can also adjust for random noise by using a model derived from the data, and corrects for temporal trends and confounding related to age, sex, and other variables by stratifying over 900 categories. Signals can then be compared with or used in conjunction with other sources (e.g. clinical trials, general practice databases) to further study the adverse‐event risk. The example of pancreatitis risk with atypical antipsychotics, valproic acid, and valproate is used to discuss the strengths and limitations of MGPS versus traditional methods. Validated data mining techniques offer great promise to enhance pharmacovigilance practices.